GSK962040 50 mg
113445
Phase 2 small_molecule terminated
Quick answer
GSK962040 50 mg for Gastroparesis is a Phase 2 program (small_molecule) at GlaxoSmithKline with 2 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline
- Indication
- Gastroparesis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated